<?xml version='1.0' encoding='utf-8'?>
<document id="27821711"><sentence text="Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction Metabolized." /><sentence text="Basimglurant, a novel mGlu5-negative allosteric modulator under development for the treatment of major depressive disorder, is cleared via cytochrome P450 (P450)-mediated oxidative metabolism" /><sentence text=" Initial enzyme phenotyping studies indicated that CYP3A4/5 dominates basimglurant metabolism and highlights a risk for drug-drug interactions when it is comedicated with strong CYP3A4/5 inhibitors or inactivators; however, a clinical drug-drug interaction (DDI) study using the potent and selective CYP3A4/5 inhibitor ketoconazole resulted in an area under the curve (AUC) AUCi/AUC ratio of only 1"><entity charOffset="319-331" id="DDI-PubMed.27821711.s3.e0" text="ketoconazole" /></sentence><sentence text="24" /><sentence text=" A further study using the CYP3A4 inducer carbamazepine resulted in an AUCi/AUC ratio of 0"><entity charOffset="42-55" id="DDI-PubMed.27821711.s5.e0" text="carbamazepine" /></sentence><sentence text="69" /><sentence text=" More detailed in vitro enzyme phenotyping and kinetics studies showed that, at the low concentrations attained clinically, basimglurant metabolic clearance is catalyzed mainly by CYP1A2" /><sentence text=" The relative contributions of the enzymes were estimated as 70:30 CYP1A2:CYP3A4/5" /><sentence text=" Using this information, a clinical study using the CYP1A2 inhibitor fluvoxamine was performed, resulting in an AUCi/AUC ratio of 1"><entity charOffset="69-80" id="DDI-PubMed.27821711.s9.e0" text="fluvoxamine" /></sentence><sentence text="60, confirming the role of CYP1A2 and indicating a balanced DDI risk profile" /><sentence text=" Basimglurant metabolism kinetics show enzyme dependency: CYP1A2-mediated metabolism follows Michaelis-Menten kinetics, whereas CYP3A4 and CYP3A5 follow sigmoidal kinetics [with similar constant (KM) and S50 values]" /><sentence text=" The interplay of the different enzyme kinetics leads to changing fractional enzyme contributions to metabolism with substrate concentration, even though none of the metabolic enzymes is saturated" /><sentence text=" This example demonstrates the relevance of non-Michaelis-Menten P450 enzyme kinetics and highlights the need for a thorough understanding of metabolism enzymology to make accurate predictions for human metabolism in vivo" /><sentence text="" /></document>